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Sudden cardiac death is a rare but catastrophic event in children and young adults (o35
years) with the incidence ranging between 0.8 and 2.8/100,000 person-years. Considering
the frequent genetic background of potentially lethal cardiovascular disease in these
patients, all attempts should be made to determine the risk for remaining family members.
A population-based approach consists of screening young individuals being at higher risk
(e.g. athletes) for potentially lethal cardiovascular disorders. The following text will analyse
the efficacy of both approaches using currently available data.
& 2012 The Czech Society of Cardiology. Published by Elsevier Urban & Partner Sp.z.o.o. All
rights reserved.1. Introduction
Sudden cardiac death (SCD) is a natural death from cardiac
causes, heralded by abrupt loss of consciousness within one
hour of the onset of acute symptoms [1]. Sudden death of a
child and young adult is a tragedy for the rest of his or her
family. Considering frequent genetic basis of conditions
leading to SCD in the young [2–5] it is of great importance
to examine the rest of the family for the presence of a
potentially life threatening cardiac disease. The aim of this
article is to summarise our current knowledge of the epide-
miology and prevention of SCD in children and young adults,
focusing on two different strategies: family risk assessment
and screening for persons at risk in the general population.2. Epidemiology
The incidence of SCD in children and young adults (o35 years)
varies, according to the literature, between 0.8 and 2.8/100,000ech Society of Cardiology
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eter.kubus@lfmotol.cuni.cperson-years [6]. Ischaemic heart disease and dilated cardio-
myopathy is the most common cause of SCD in the elderly
population. On the contrary, inherited or congenital cardiovas-
cular disorders are the main cause of SCD in children and
young adults [7]. The athletes participating in competitive
sports, requiring systematic training and regular competition
against others, are particularly at higher risk of SCD [8,9].
In 1988 Thiene et al. have published the study of 60 persons
(o35 years) who had died suddenly in the Veneto Region
(Italy) [10]. They found morphologic features of right ventri-
cular cardiomyopathy (ARVC) in 12 of them. The authors
suggested that ARVC might have been more frequent than
previously thought and represented an important cause of
sudden death in the young. A systematic nationwide pre-
participation screening of young competitive athletes was
introduced in Italy in 1982. In addition to the personal history
and physical examination, 12-lead ECG has been included.
The aim was to identify the asymptomatic athletes with a
potentially lethal cardiovascular disorder and to prevent SCD
through the disqualification from the competitive sport. Published by Elsevier Urban & Partner Sp.z.o.o. All rights
420 22443 2914.
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Corrado et al. have evaluated the impact of this screening by
analysis of the trends in incidence rates and cardiovascular
causes of SCD [11]. They focused on athletic and non-athletic
population, aged between 12 and 35 years, in the Veneto
region (period 1979–2004). A parallel study examined trends
in cardiovascular causes of disqualification from competitive
sports in 42,386 athletes undergoing preparticipation screen-
ing at Center for Sports Medicine in Padua. The annual
incidence in athletes decreased from 3.6/100,000 person-
years in 1979–1980 (before the screening period) to 0.4/
100,000 person-years during period 2003–2004. The incidence
of SCD in the unscreened non-athletic population did not
change significantly (0.77 and 0.81/100,000 person-years). The
decrease in mortality was mainly due to the reduction of SCD
from cardiomyopathies, which were the most common cause
of SCD (followed by coronary artery disease, myocarditis,
cardiac conduction disease, congenital coronary anomalies
and mitral valve prolapse). Potentially inaccurate estimation
of a true incidence of SCD, related to a relatively short pre-
screening period, was the main limitation of the study.
Using targeted retrospective searches from various sources,
Maron et al. have identified 1866 athletes from the USA
(mean age 1976 years), who had died suddenly or survived
a cardiac arrest during the period between 1980 and 2006 [12].
Sudden death due to cardiovascular disease was probably or
definitely found in 1049 (56%). Of these, 690 deaths could be
reliably (and other 359 most likely) attributed to cardiovas-
cular disease. The incidence of sudden death in these
individuals (estimated population of 10.7 million athletes
aged o39 years in the USA) was 0.61/100,000 person-years.
The absolute number of sudden deaths due to cardiovascular
causes was o100 per year in this population. The authors
proposed the introduction of a systematic mandatory
national reporting system for SCD in young competitive
athletes. Among 690 SCD, hypertrophic cardiomyopathy was
the most common cardiovascular cause of sudden death
(36%), followed by coronary artery anomalies of wrong sinus
origin (17%), possible evidence for hypertrophic cardiomyo-
pathy at autopsy with mildly increased left ventricular wall
thickness (8%), myocarditis (6%), ARVC (4%), ion channelopa-
thies (4%), mitral valve prolapse (4%), coronary artery disease,
aortic rupture, aortic stenosis, dilated cardiomyopathy and
Wolff–Parkinson–White syndrome. Among 1049 cases of
probable or definite cardiovascular death, 65% were o17
years of age, 29% were between 18 and 25 years, 7% were 26
and older. Male athletes represented 89% of cases of sudden
cardiovascular death, but the proportion of females has
increased to 12% in the period 2000–2006. Despite the absence
of ECG as a part of the pre-participation screening in the USA
(only personal history and physical examination were used),
the study showed a relatively low number of cardiovascular
sudden deaths in young athletes, which is in clear contrast
with findings of Italian study in the pre-screening period [11].
In a population-based study (2010), Winkel et al. have
evaluated the incidence of SCD in all death persons aged
1–35 years in Denmark (5.38 million inhabitants) during the
period 2000–2006 [13]. They identified 625 cases of sudden
unexpected death (10% of all deaths). Of the 469 autopsied
cases, SCD was attributed to 314 (67%), with histopathologyperformed in 96% of them. The incidence of SCD was 1.9/
100,000 person-years (2.8/100,000 after including non-autop-
sied cases of sudden unexpected deaths, which corresponds
to 7% of all deaths in persons aged 1–35 years), thus higher
than previously reported in a general population. The median
age of the SCD population was 29 years and the risk of SCD
was more than 10 times higher for persons aged 30–35 years,
compared to persons aged 1–10 years. Male gender was
present in 67% of the SCD cases and there was no difference
in age distribution between males and females. Of the SCD
group, 61% had no previous medical history. Death occurred
in awake resting state in 50%, during sleep in 34% and during
moderate to high intensity activity including sport in 11% of
the cases. Of the 314 autopsied persons suffering from SCD,
ischaemic heart disease was the cause of death in 13%,
myocarditis in 7%, thoracic aortic dissection in 7%, hyper-
trophic cardiomyopathy in 6% and ARVC in 5%. Sudden
unexplained cardiac death represented the remaining 43%.
The authors suggested that a relevant part of these deaths
could have been attributed to primary electrical disease.
Steinvil et al. have analysed the impact of the mandatory pre-
participation screening of competitive athletes, enacted in 1997
in Israel [14]. The resting and exercise ECG was included in the
screening programme. They compared the number of documen-
ted sudden death or cardiac arrest in the pre-screening and
mandatory screening period (1985–1997 and 1997–2009, respec-
tively), based on a systematic search of the two main news-
papers in Israel. The difference in the average yearly incidence of
sudden death or cardiac arrest in pre-screening and screening
period was not significant (2.54 and 2.66/100,000 person-years,
respectively). The method of data collection (uncertain number
of cardiac events and a rough estimation of the population of
competitive athletes) was the main limitation of this study based
on observational data and retrospective analysis.3. Prevention
Using the data of Winckel et al. [13] we may expect about 140
cases of SCD per year in the population aged 1–35 years in the
Czech Republic (or 100 cases based on their data of autopsied
cases). Taking into account the frequent genetic basis of the
conditions leading to SCD in children and young adults [7],
every attempt should be made to prevent the repetition of the
tragedy in surviving relatives. Furthermore, screening strate-
gies for potentially life-threatening cardiovascular disorders
may be considered either in the whole population or in
persons being at higher risk (e.g. competitive athletes) based
on the evaluation of their effectiveness.
3.1. Family risk assessment
Between 10% and 30 (40)% of sudden deaths in the young
remain unexplained after a thorough autopsy thus referred as
sudden unexplained death (SUD) or as sudden infant death
syndrome (SIDS) in children aged o1 year [13,15]. According to
two recent studies, an inherited cardiac disease (ARVC, hyper-
trophic cardiomyopathy) or a primary electrical disease (long
QT syndrome—LQTS, catecholaminergic polymorphic ventricu-
lar tachycardia—CPVT, Brugada syndrome) was found in 22%
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The evaluation of first-degree relatives of SUD victims showed
the presence of cardiac symptoms in 27% (palpitations, pre-
syncope, syncope), and sudden unexpected death in 6% [3].
Behr et al. have evaluated 57 consecutively referred families
with sudden arrhythmic death syndrome (SADS). They found
an inheritable heart disease in 53% of them (LQTS, ARVC,
Brugada, other cardiomyopathies) [4]. Tester and Ackerman
have performed a molecular autopsy of 49 victims of SUD
(average age at death 14.2 years). They discovered a gene
mutation responsible for a potentially lethal arrhythmia in
one-third of them (LQTS and CPVT-associated mutations in
20% and 15%, respectively) [5].
When SCD is found to be the likely cause of death, it is
essential to inform the relatives as soon as possible. The
general practitioner should communicate with the family and
provide access to the specialist. The cardiologist should assess
the detailed personal and family history and provide a risk
assessment for the close relatives in a specialised cardiologic
centre, including the genetic testing in accordance with the
guidelines or expert consensus statement [16]. The cooperation
of the family members is crucial. The pathologist should
provide evidence of a structural heart disease, if present, and
initiate molecular genetic examination in indicated cases (this
examination is not yet routinely performed in this country).
In the Czech Republic, a structural autopsy is mandatory in
case of death under 18 years of age, or unexplained death
outside the hospital. According to the law recently enacted,
the autopsy is performed by the forensic pathologist in case
of sudden and unexpected death, unexplained by external
inspection of the corpse. A pathologist is obliged to inform a
general practitioner in writing about the cause of death. A
physician carrying out an inspection of the deceased is
obliged to inform a closely related person, eventually the
police. If transferred into real life, these regulations may
positively impact the process of evaluation of the potentially
affected relatives.
3.2. Screening
The purpose of screening is early detection of cardiovascular
disease potentially leading to SCD. In the population of
competitive athletes individuals with such a condition
should be temporarily or permanently disqualified from
competitive sport activities and, if necessary, treated ade-
quately [17,18].
The evidence about SCD incidence in competitive athletes
is generally hampered by retrospective character of the
studies performed, as well as by questionable data collection
(information from newspapers/media, single-centre studies
or registries, problematic definition of the study population,
limited pre-screening period, seasonal variation in SCD inci-
dence), both probably leading to an underestimation of a true
SCD incidence in this group. In their prospective study,
Corrado et al. declared a 2.5 times higher risk of SCD in
adolescents and young adults participating in competitive
sport activities [11]. Previously asymptomatic cardiovascular
abnormalities, especially cardiomypathies and coronary
artery disease, were the main cause of SCD. Similar to other
published reports, a significant predominance of males wasfound, which probably corresponds to a different male to
female ratio engaged in competitive sport activities, more
vigorous physical exertion in males, and eventually to a
higher prevalence and/or phenotypic expression of cardiac
abnormalities leading to SCD (cardiomyopathy, ischaemic
heart disease, LQTS) in males [8,13,19–21].
If a cardiac abnormality is identified or suspicious, a further
non-invasive (echocardiography, 24-h ambulatory ECG mon-
itoring, exercise testing) or invasive (electrophysiologic study,
coronary angiography, ventriculography, endomyocardial
biopsy) should be considered to confirm or rule it out.
The competent working groups of the European Society of
Cardiology (ESC) has adopted a proposal for a common
European protocol for the initial cardiovascular evaluation
of young competitive athletes, which consists of complete
personal and family history, physical examination (including
blood pressure measurement) and 12-lead ECG [6]. The
screening should be performed (by a physician trained in
identifying the signs of potentially lethal cardiac abnormal-
ities) at the beginning of competitive sport activity, and
repeated at least every two years. The implementation of
ECG according to ESC criteria [22] is particularly based on the
Italian experience which showed a significant decrease in
mortality due to the reduction of SCD from cardiomyopathies
in young athletes [11]. ECG abnormalities have been also
described in patients with ARVC and some genetic arrhyth-
mic syndromes (e.g. LQTS, Brugada syndrome).
The recommendation of the Council on Nutrition, Physical
Activity, and Metabolism, AHA (American Heart Association)
consists of 12 items (8 for personal and family history and 4
for physical examination). Positive finding in any of these
items justify the examiner to refer the person to a cardiolo-
gist. The physicians are currently not mandated to adopt the
ESC guidelines. Arguments against a routine application of
ECG testing are mainly based on the enormous financial
burden of such a nationwide screening programme, which
is partly related to the size of the competitive athletes
population, partly to the relatively low prevalence of cardio-
vascular abnormalities leading potentially to SCD, low speci-
ficity of ECG as a screening test in athletes (due to high rate of
ECG alterations associated with the normal physiological
adaptations of the trained heart) and finally to the limited
administrative and medical human resources [23]. The gen-
eration of borderline or false-positive results (8.8–25% accord-
ing to different reports) will trigger further diagnostic tests in
likely healthy persons and carry an emotional, financial and
medical burden for the athlete and his or her family
[11,23–25]. The cost-effectiveness of a pre-participation
screening programme in young athletes including 12-lead
ECG (in conformity with the ESC [6] recommendation) has
been recently evaluated by Wheeler et al. [26] calculating a
price of 100,000 USD per one life-year saved.
Currently available studies showing a positive effect of the
pre-participation screening [6,9] have important limitations
including inaccurate data collection, ambiguous subject defi-
nition, temporarily limited pre-screening period (the influ-
ence of a seasonal variation in SCD incidence), and eventually
a mortality bias (false-positive impact of a screening pro-
gramme linked to the natural variation of SCD incidence
within the pre-screening and screening period).
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The evaluation of the young (o35 years) victims of sudden
cardiac death and their relatives is an effective strategy for
the detection of familiar cardiovascular disorders leading to
SCD. As for the Czech Republic, apart from limited access to
some diagnostic methods (molecular autopsy), the commu-
nication among individual health care providers, as well as
the communication towards the affected families, is one of
the main problems in this process. The compliance of the
affected family will likely play a crucial role as well.
The introduction of a pre-participation screening programme
in risk groups (e.g. competitive athletes) with the inclusion of a
12-lead ECG may enhance the detection of asymptomatic
individuals with potentially lethal cardiovascular disease.
Nevertheless, taking into account the organisational and
financial aspects, as well as a high number of false-positive
findings, the cost-effectiveness of such an approach has not
been definitely confirmed yet. The present ESC recommenda-
tions are based on a single large study. The practical imple-
mentation of the screening programme requires a large
number of the physicians providing the ECG analysis. The
implementation of such screening programme should be
thoroughly debated and all interested parties (including pro-
fessional associations, health care providers and insurance
companies) should participate in the discussion.Funding
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